Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
Part of paid clinical trials in Dallas, Texas.
- Sponsor
- Deborah Farr, MD
- Study ID
- NCT05245812
- Status
- Recruiting
Conditions
- Breast Cancer
- High Risk of Breast Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- da Vinci SP Surgical System — DEVICEThis is a software-controlled, electro- mechanical system designed for surgeons to perform single port minimally invasive surgery.
Study Details
This is a single arm, single-center, prospective clinical trial designed to track the peri, post-operative and oncologic outcomes when utilizing the da-Vinci single port (SP) robotic platform to perform robotic nipple sparing mastectomy (rNSM) and immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (ADM - Alloderm), for patients with breast cancer as well as those with a high risk for breast cancer. Safety and feasibility measures will be measured as primary outcome measures. Oncological and patient satisfaction outcome measures will be measured. Our hypothesis is that SPr-NSM is equal to open NSM in terms of safety, feasibility and oncological outcomes with improved patient satisfaction as measured by nipple sensation and patient reported outcomes.
Key Dates
- Start date
- Mar 8, 2022
- Status verified
- Jul 2025
- Primary completion
- Feb 28, 2027
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment arm (SPrNSM)Patients will undergo Single Port robotic Nipple Sparing Mastectomy (SPrNSM) with immediate breast reconstruction with tissue expanders/implants and acellular dermal matrix (Alloderm)
Primary Outcome Measure
Number of participants who complete single port nipple sparing mastectomy (SPrNSM) [ Time Frame: Date of surgery (Day 1) ]
Central Contacts
- Deborah Farr, MD, FACS214-648-4133
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UT Southwestern | Dallas | Texas | 75390 | Deborah E Farr, MD |
Find similar trials in Dallas, TX
Related Studies
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Birmingham, Alabama
- MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression ProfilesRecruiting · Agendia · Birmingham, Alabama
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska